- Home
- CHI vs ORIC Comparison
CHI vs ORIC Comparison
Compare CHI & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | ORIC |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 849.6M | 783.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CHI | ORIC |
|---|---|---|
| Price | $10.77 | $8.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 186.2K | ★ 1.4M |
| Earning Date | 01-01-0001 | 02-17-2026 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.70 | $3.90 |
| 52 Week High | $11.61 | $14.93 |
Technical Indicators
Market Signals| Indicator | CHI | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 28.95 |
| Support Level | $10.42 | $7.98 |
| Resistance Level | $11.00 | $8.62 |
| Average True Range (ATR) | 0.15 | 0.46 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 55.17 | 13.26 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.